Anti-inflammatory response after infusion of XXXX soluble tumor necrosis factor receptor fusion protein for severe @entity295 .

@entity1 @entity650 @entity295 @entity310 @entity1193 @entity10736
OBJECTIVES: To investigate the effects of Lenercept , a recombinant soluble TNF receptor @entity10736 fused to an immunoglobulin heavy chain IgG1, on the balance of pro- and anti-inflammatory mediators in @entity295 . DESIGN: Post hoc analysis of a subgroup of @entity1 enrolled in a multicenter phase III, prospective, double-blind, placebo-controlled, randomized study of Lenercept in severe @entity295 . SETTING: Surgical and medical intensive care units, and postoperative recovery room of a tertiary care teaching hospital. @entity1 : A total of 57 @entity1 were enrolled in the multicenter study in our center. INTERVENTION: Septic @entity1 were randomly assigned to receive either Lenercept 0.125 mg/kg or placebo. The @entity1 were followed for up to 28 days after randomization. MEASUREMENTS AND MAIN RESULTS: Circulating levels of @entity310 , @entity650 , TNFsR75 and @entity1193 were measured before and after treatment. The two groups were comparable with regard to age, gender and diagnosis distribution. The total level of @entity310 increased significantly in treated @entity1 , compared to @entity1 receiving placebo. The levels of the other inflammatory mediators did not differ between the two groups CONCLUSIONS: Lenercept -treated @entity1 experienced a protracted @entity310 half-life, leading to higher total @entity310 levels throughout the study. However, the treatment had no effects on anti-inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic @entity1
